Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.

@article{Hisatake2017ShortTermSF,
  title={Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.},
  author={Shinji Hisatake and Takayuki Kabuki and Shunsuke Kiuchi and Takashi Oka and Shintaro Dobashi and Takahiro Fujii and Yoshihiro Iwasaki and Takanori Ikeda},
  journal={Circulation journal : official journal of the Japanese Circulation Society},
  year={2017},
  volume={81 6},
  pages={855-861}
}
BACKGROUND No studies have compared treatment efficacy between subcutaneous (SC) fondaparinux and oral edoxaban, which are categorized as factor Xa inhibitors, for venous thromboembolism (VTE) in the acute phase, and only a limited number of imaging-based quantitative studies have evaluated treatment.Methods and Results:In this open-label, randomized study, 50 patients with acute non-massive pulmonary embolism (PE) and/or deep-vein thrombosis (DVT) were assigned to fondaparinux or edoxaban… CONTINUE READING

Similar Papers

Loading similar papers…